Integra LifeSciences Holdings Corp. is a U.S.-based medical technology company focused on surgical, neurosurgical, ENT, and regenerative care products. It sells devices and biologic materials used to restore tissue, support wound healing, and enable precision surgery, with two main segments: Codman Specialty Surgical and Tissue Technologies.
−27,4 %
50,9 %
−31,6 %
+1,5 %
2.54
1.46
| % | |
|---|---|
| Codman Specialty Surgical (CSS) | 70% Market-leading surgical instruments and technologies for neurosurgery, neurocritical care, ENT, and other precision procedures. |
| Tissue Technologies (TT) | 30% Regenerative tissue products for wound reconstruction, wound care, and reconstructive surgery, including biologic materials. |
| Private Label and OEM | 10% Manufactured regenerative and wound care products sold to other medical technology companies under their own brands. |
| Advanced Wound and Reconstruction | 15% Products used in burn care, deep tissue wounds, plastic surgery, and soft tissue repair. |
| Specialty Surgical Instruments | 45% Tools and instrumentation used across precision, specialty, and general surgical procedures. |
Integra sells primarily to hospitals, integrated health networks, group purchasing organizations, surgery centers, and...
Buy neurosurgical, ENT, and wound care products for inpatient procedures and standardized clinical pathways.
Use specialty instruments and regenerative products in procedures that require precision and trusted performance.
Source products for member hospitals and health systems to manage cost and supply consistency.
Purchase specialty surgical tools and wound products for outpatient and ambulatory procedures.
Buy collagen biomaterials and manufactured components for their own branded end-market products.
Integra generates most revenue in the United States, with meaningful exposure to Europe, Asia Pacific, and the rest of...
Integra is focused on fixing operations, improving quality systems, and expanding manufacturing capacity to support...
Quality and supply issues can disrupt shipments, raise costs, and damage customer trust.
More resilient manufacturing supports product availability and reduces single-site risk.
Clinical proof and reimbursement support are key to adoption in surgical and regenerative care.
Broader geographic reach diversifies demand and supports growth beyond the U.S. market.
Integra is exposed to operational and quality execution risk because its products depend on regulated manufacturing,...
The company is remediating quality system gaps and transferring production across sites, which can interrupt supply and raise costs.
Tariffs, trade barriers, inflation, and geopolitical instability can affect sourcing, pricing, and customer demand.
Management recorded a large goodwill impairment in 2025, showing sensitivity to valuation assumptions and operating performance.
A meaningful share of revenue and costs is outside the U.S., and borrowing costs have risen.
A breach or outage could interrupt transaction processing, manufacturing, and product supply.
: 28.4.2026